ALMS: Envudicitinib shows efficacy in lupus and psoriasis subgroups
ALMS said its phase IIb lupus trial failed overall, citing a high proportion of interferon signature negative patients, but showed strong efficacy in interferon signature positive subgroups. Regulatory discussions are planned, and a psoriasis NDA submission is planned.